Cargando…

Endometrial Heparin-Binding Epidermal Growth Factor Gene Expression and Hormone Level Changes in Implantation Window of Obese Women with Polycystic Ovarian Syndrome

Introduction: Polycystic ovarian syndrome (PCOS) is a common endocrine disorder amongst reproductive-age women, and 61% to 76% of women with PCOS are obese. Obese women with PCOS are usually burdened with infertility problems due to implantation failure. Thus, progesterone treatment is usually used...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutaji, Zulazmi, Abu, Muhammad Azrai, Sayutti, Nurainie, Elias, Marjanu Hikmah, Ahmad, Mohd Faizal, Nur Azurah, Abdul Ghani, Chew, Kah Teik, Abdul Karim, Abdul Kadir, Aziz, Nor Haslinda Abd, Mokhtar, Mohd Helmy, Zin, Reena Rahayu Md, Hussein, Zeti Azura Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953163/
https://www.ncbi.nlm.nih.gov/pubmed/36830813
http://dx.doi.org/10.3390/biomedicines11020276
_version_ 1784893810017304576
author Sutaji, Zulazmi
Abu, Muhammad Azrai
Sayutti, Nurainie
Elias, Marjanu Hikmah
Ahmad, Mohd Faizal
Nur Azurah, Abdul Ghani
Chew, Kah Teik
Abdul Karim, Abdul Kadir
Aziz, Nor Haslinda Abd
Mokhtar, Mohd Helmy
Zin, Reena Rahayu Md
Hussein, Zeti Azura Mohamed
author_facet Sutaji, Zulazmi
Abu, Muhammad Azrai
Sayutti, Nurainie
Elias, Marjanu Hikmah
Ahmad, Mohd Faizal
Nur Azurah, Abdul Ghani
Chew, Kah Teik
Abdul Karim, Abdul Kadir
Aziz, Nor Haslinda Abd
Mokhtar, Mohd Helmy
Zin, Reena Rahayu Md
Hussein, Zeti Azura Mohamed
author_sort Sutaji, Zulazmi
collection PubMed
description Introduction: Polycystic ovarian syndrome (PCOS) is a common endocrine disorder amongst reproductive-age women, and 61% to 76% of women with PCOS are obese. Obese women with PCOS are usually burdened with infertility problems due to implantation failure. Thus, progesterone treatment is usually used to improve implantation rates. Although Hb-EGF expression is actively involved in endometrial receptivity and implantation, the data on heparin-binding epidermal growth factor (Hb-EGF) expression following progesterone therapy in obese women with PCOS are still lacking. Objective: To investigate the changes in serum follicle-stimulating hormone (FSH), luteinising hormone (LH), dehydroepiandrosterone sulphate (DHEA), progesterone and oestradiol levels and Hb-EGF expression in obese women with PCOS during the implantation window following progesterone therapy. Method: A total of 40 participants aged 18–40 years old were recruited following the provision of written consent. The participants were divided into the obese PCOS, normal-weight PCOS, obese fertile and normal-weight fertile groups. First blood collection was done before ovulation. Then, daily oral micronised progesterone (Utrogestan 200 mg) was given to the PCOS group for 10 days. The treatment was followed by a second blood collection and endometrial tissue sampling by using a Pipelle de Cornier catheter. In the fertile group, ovulation was confirmed by using ultrasound, and a second blood sample was collected on days 7 to 9 postovulation. The serum levels of FSH, LH, DHEA, progesterone and oestradiol were measured in all participants. Wilcoxon signed-rank test was used to compare FSH, LH, DHEA, progesterone and oestradiol levels during pre- and postovulation. Mann–Whitney test was performed to compare FSH, LH, DHEA, progesterone and oestradiol levels between two groups: (1) the PCOS group and the fertile group, (2) the obese PCOS group and the non-obese PCOS group and (3) the obese group and the non-obese fertile group. Result: Serum FSH levels were lower in obese women in their follicular phase than in women with normal weight regardless of their PCOS status, whereas serum LH/FSH ratios and DHEA levels were higher in women with PCOS than in women without PCOS. However, endometrial Hb-EGF expression was lower in the obese PCOS group than in the normal-weight PCOS group. Conclusions: Different patterns of hormonal levels and Hb-EGF expression levels were seen between the studied groups. However, further in vitro and in vivo studies are needed to investigate the mechanism underlying the changes in FSH, LH/FSH ratio, DHEA and Hb-EGF expression in PCOS after progesterone treatment.
format Online
Article
Text
id pubmed-9953163
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99531632023-02-25 Endometrial Heparin-Binding Epidermal Growth Factor Gene Expression and Hormone Level Changes in Implantation Window of Obese Women with Polycystic Ovarian Syndrome Sutaji, Zulazmi Abu, Muhammad Azrai Sayutti, Nurainie Elias, Marjanu Hikmah Ahmad, Mohd Faizal Nur Azurah, Abdul Ghani Chew, Kah Teik Abdul Karim, Abdul Kadir Aziz, Nor Haslinda Abd Mokhtar, Mohd Helmy Zin, Reena Rahayu Md Hussein, Zeti Azura Mohamed Biomedicines Article Introduction: Polycystic ovarian syndrome (PCOS) is a common endocrine disorder amongst reproductive-age women, and 61% to 76% of women with PCOS are obese. Obese women with PCOS are usually burdened with infertility problems due to implantation failure. Thus, progesterone treatment is usually used to improve implantation rates. Although Hb-EGF expression is actively involved in endometrial receptivity and implantation, the data on heparin-binding epidermal growth factor (Hb-EGF) expression following progesterone therapy in obese women with PCOS are still lacking. Objective: To investigate the changes in serum follicle-stimulating hormone (FSH), luteinising hormone (LH), dehydroepiandrosterone sulphate (DHEA), progesterone and oestradiol levels and Hb-EGF expression in obese women with PCOS during the implantation window following progesterone therapy. Method: A total of 40 participants aged 18–40 years old were recruited following the provision of written consent. The participants were divided into the obese PCOS, normal-weight PCOS, obese fertile and normal-weight fertile groups. First blood collection was done before ovulation. Then, daily oral micronised progesterone (Utrogestan 200 mg) was given to the PCOS group for 10 days. The treatment was followed by a second blood collection and endometrial tissue sampling by using a Pipelle de Cornier catheter. In the fertile group, ovulation was confirmed by using ultrasound, and a second blood sample was collected on days 7 to 9 postovulation. The serum levels of FSH, LH, DHEA, progesterone and oestradiol were measured in all participants. Wilcoxon signed-rank test was used to compare FSH, LH, DHEA, progesterone and oestradiol levels during pre- and postovulation. Mann–Whitney test was performed to compare FSH, LH, DHEA, progesterone and oestradiol levels between two groups: (1) the PCOS group and the fertile group, (2) the obese PCOS group and the non-obese PCOS group and (3) the obese group and the non-obese fertile group. Result: Serum FSH levels were lower in obese women in their follicular phase than in women with normal weight regardless of their PCOS status, whereas serum LH/FSH ratios and DHEA levels were higher in women with PCOS than in women without PCOS. However, endometrial Hb-EGF expression was lower in the obese PCOS group than in the normal-weight PCOS group. Conclusions: Different patterns of hormonal levels and Hb-EGF expression levels were seen between the studied groups. However, further in vitro and in vivo studies are needed to investigate the mechanism underlying the changes in FSH, LH/FSH ratio, DHEA and Hb-EGF expression in PCOS after progesterone treatment. MDPI 2023-01-19 /pmc/articles/PMC9953163/ /pubmed/36830813 http://dx.doi.org/10.3390/biomedicines11020276 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sutaji, Zulazmi
Abu, Muhammad Azrai
Sayutti, Nurainie
Elias, Marjanu Hikmah
Ahmad, Mohd Faizal
Nur Azurah, Abdul Ghani
Chew, Kah Teik
Abdul Karim, Abdul Kadir
Aziz, Nor Haslinda Abd
Mokhtar, Mohd Helmy
Zin, Reena Rahayu Md
Hussein, Zeti Azura Mohamed
Endometrial Heparin-Binding Epidermal Growth Factor Gene Expression and Hormone Level Changes in Implantation Window of Obese Women with Polycystic Ovarian Syndrome
title Endometrial Heparin-Binding Epidermal Growth Factor Gene Expression and Hormone Level Changes in Implantation Window of Obese Women with Polycystic Ovarian Syndrome
title_full Endometrial Heparin-Binding Epidermal Growth Factor Gene Expression and Hormone Level Changes in Implantation Window of Obese Women with Polycystic Ovarian Syndrome
title_fullStr Endometrial Heparin-Binding Epidermal Growth Factor Gene Expression and Hormone Level Changes in Implantation Window of Obese Women with Polycystic Ovarian Syndrome
title_full_unstemmed Endometrial Heparin-Binding Epidermal Growth Factor Gene Expression and Hormone Level Changes in Implantation Window of Obese Women with Polycystic Ovarian Syndrome
title_short Endometrial Heparin-Binding Epidermal Growth Factor Gene Expression and Hormone Level Changes in Implantation Window of Obese Women with Polycystic Ovarian Syndrome
title_sort endometrial heparin-binding epidermal growth factor gene expression and hormone level changes in implantation window of obese women with polycystic ovarian syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953163/
https://www.ncbi.nlm.nih.gov/pubmed/36830813
http://dx.doi.org/10.3390/biomedicines11020276
work_keys_str_mv AT sutajizulazmi endometrialheparinbindingepidermalgrowthfactorgeneexpressionandhormonelevelchangesinimplantationwindowofobesewomenwithpolycysticovariansyndrome
AT abumuhammadazrai endometrialheparinbindingepidermalgrowthfactorgeneexpressionandhormonelevelchangesinimplantationwindowofobesewomenwithpolycysticovariansyndrome
AT sayuttinurainie endometrialheparinbindingepidermalgrowthfactorgeneexpressionandhormonelevelchangesinimplantationwindowofobesewomenwithpolycysticovariansyndrome
AT eliasmarjanuhikmah endometrialheparinbindingepidermalgrowthfactorgeneexpressionandhormonelevelchangesinimplantationwindowofobesewomenwithpolycysticovariansyndrome
AT ahmadmohdfaizal endometrialheparinbindingepidermalgrowthfactorgeneexpressionandhormonelevelchangesinimplantationwindowofobesewomenwithpolycysticovariansyndrome
AT nurazurahabdulghani endometrialheparinbindingepidermalgrowthfactorgeneexpressionandhormonelevelchangesinimplantationwindowofobesewomenwithpolycysticovariansyndrome
AT chewkahteik endometrialheparinbindingepidermalgrowthfactorgeneexpressionandhormonelevelchangesinimplantationwindowofobesewomenwithpolycysticovariansyndrome
AT abdulkarimabdulkadir endometrialheparinbindingepidermalgrowthfactorgeneexpressionandhormonelevelchangesinimplantationwindowofobesewomenwithpolycysticovariansyndrome
AT aziznorhaslindaabd endometrialheparinbindingepidermalgrowthfactorgeneexpressionandhormonelevelchangesinimplantationwindowofobesewomenwithpolycysticovariansyndrome
AT mokhtarmohdhelmy endometrialheparinbindingepidermalgrowthfactorgeneexpressionandhormonelevelchangesinimplantationwindowofobesewomenwithpolycysticovariansyndrome
AT zinreenarahayumd endometrialheparinbindingepidermalgrowthfactorgeneexpressionandhormonelevelchangesinimplantationwindowofobesewomenwithpolycysticovariansyndrome
AT husseinzetiazuramohamed endometrialheparinbindingepidermalgrowthfactorgeneexpressionandhormonelevelchangesinimplantationwindowofobesewomenwithpolycysticovariansyndrome